Tumor necrosis factor (TNF) system levels in human immunodeficiency virus-infected patients during highly active antiretroviral therapy: Persistent TNF activation is associated with virologic and immunologic treatment failure
P. Aukrust et al., Tumor necrosis factor (TNF) system levels in human immunodeficiency virus-infected patients during highly active antiretroviral therapy: Persistent TNF activation is associated with virologic and immunologic treatment failure, J INFEC DIS, 179(1), 1999, pp. 74-82
Because persistent tumor necrosis factor (TNF)-alpha activation may play a
pathogenic role in human immunodeficiency virus infection, TNF component le
vels were assessed over 78 weeks in plasma and peripheral blood mononuclear
cells (PBMC) during highly active antiretroviral therapy (HAART) in 40 HIV
-infected patients. HAART induced a significant decline in plasma levels of
TNF-alpha and soluble TNF receptors and was associated with a fall in the
abnormally increased unstimulated and a rise in the abnormally low Mycobact
erium avium complex-purified-protein derivative-stimulated TNF-alpha releas
ed from PBMC, However, concentrations of these TNF components were not norm
alized. Patients with virologic and immunologic treatment failure after 52
weeks had higher levels of several TNF components than other patients early
after initiation of therapy, also during periods with adequate virologic r
esponse. Although TNF components significantly decreased during HAART, thes
e results support data indicating that full immunologic normalization is no
t achieved during such therapy. The persistent activation of the TNF system
in a subgroup of persons may be involved in treatment failure.